A Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.
HX-1171
A Phase I Clinical Study, Randomized, Single-blind,Placebo-controlled, Multiple Doses, Dose Escalation Study fo the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
This study is designed to multiple dose and dose escalation study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 20, 2013
CompletedFirst Posted
Study publicly available on registry
June 28, 2013
CompletedJune 28, 2013
June 1, 2013
June 20, 2013
June 20, 2013
Conditions
Interventions
Anti-oxidatant, Anti-inflamation
Eligibility Criteria
You may qualify if:
- Adult males aged 20 to 40 years at screening.
- Be able to comply with the requirement of the study. Subject must provide written informed consent prior to study participation.
You may not qualify if:
- History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or gastrointestinal disorders.
- History of known hypersensitivity to drugs including HX-1171.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Asan Medical Center
Special City of Seoul, South Korea
Related Links
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Kyun-Seop Bae, M.D., Ph.D
Asan Medical Center
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2013
First Posted
June 28, 2013
Last Updated
June 28, 2013
Record last verified: 2013-06